The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- Coalition to Transform Clinical Trial Engagement Launches “Champions for Change – PTO Initiative
- Foundation for Sarcoidosis Research Expands Board of Directors with New Leaders in 2025
- FSR Research Report: April’s Awareness Month 2025
- Diagnosed at 12: My Journey Growing Up with Sarcoidosis
- FSR, Walgreens, & Cedars-Sinai Provide Free N95 Masks to Protect LA Wildfire Survivors